Skip to main content

Illumina Posts Surge in Q1 Revenues, Narrowed Losses

NEW YORK, April 20 (GenomeWeb News) - Illumina today reported a 153 percent increase in revenues for its first fiscal quarter of 2004, accompanied by narrowed losses.

For the quarter ended March 28, 2004, Illumina posted revenue of $10.8 million, up sharply from $4.3 million for the same period in 2003. Product revenue was $8.9 million for the quarter, up from $1.4 million in the first quarter 2003, while service revenue dipped slightly, to $1.2 million, from $1.9 million in the same period last year.

The company's net loss for the quarter was $3.9 million, or $0.12 per share, compared to $9.0 million, or $0.28 per share, in the first quarter of 2003.

Illumina reported $5.2 million in R&D expenses for the first quarter of 2004, down from $5.7 million in the same period of 2003.

Illumina's cash and investments as of March 28, 2004, were $27.9 million, compared to $32.9 million at the end of 2003. The company said that its cash holdings, including long-term restricted investments, totaled $40.0 million at the end of the quarter.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.